Biogen 配当と自社株買い
配当金 基準チェック /06
Biogen配当金を支払った記録がありません。
主要情報
n/a
配当利回り
n/a
バイバック利回り
| 総株主利回り | n/a |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブ更新 • May 04
BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential
Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.
ナラティブ更新 • Apr 20
BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism
Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.Seeking Alpha • Apr 06
Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease
Summary Eisai (ESALF) and Biogen (BIIB) have presented inconsistent efficacy claims for Leqembi in Alzheimer's, particularly regarding APOE4 genetic subgroups. Real-world data may reveal Leqembi is only marginally effective for APOE4 single-copy carriers, with little benefit for non-carriers or double-copy carriers. BIIB may be more resilient than ESALF to negative Leqembi developments due to pipeline diversity, but no near-term catalysts are evident for BIIB stock movement. Efforts to expand Leqembi’s market may be misguided; regulatory scrutiny and emerging alternatives could further limit its commercial potential. Read the full article on Seeking Alphaナラティブ更新 • Apr 05
BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism
The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.
新しいナラティブ • Mar 31
Biogen Inc. (BIIB): The "Post-MS" Pivot and the Alzheimer’s Momentum
Biogen Inc. (BIIB) is navigating a high-stakes transition year in 2026, closing the March 31, 2026, session at $178.98 USD on the NASDAQ.ナラティブ更新 • Mar 22
BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism
Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.
ナラティブ更新 • Mar 07
BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside
The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.ナラティブ更新 • Feb 21
BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk
The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.分析記事 • Feb 13
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings
Shareholders appeared unconcerned with Biogen Inc.'s ( NASDAQ:BIIB ) lackluster earnings report last week. We think...ナラティブ更新 • Feb 07
BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential
Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.ナラティブ更新 • Jan 23
BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations
Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.ナラティブ更新 • Jan 09
BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook
Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.ナラティブ更新 • Dec 24
BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance
Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.ナラティブ更新 • Dec 10
BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead
Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.ナラティブ更新 • Nov 26
BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead
Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.ナラティブ更新 • Nov 12
BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025
Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.ナラティブ更新 • Oct 29
Easing Policy Risks And New Therapy Launches Will Drive Shares Higher
Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.ナラティブ更新 • Oct 15
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.ナラティブ更新 • Sep 20
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.ナラティブ更新 • Sep 05
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.分析記事 • Jun 17
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 25
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Summary Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple Sclerosis treatments face patent expirations and competition, pressuring revenue; new Alzheimer's Disease and rare disease treatments could drive future growth. Financially, Biogen remains profitable with strong FCF, but reduced R&D spending and lack of insider buying or share buybacks are concerning. I rate BIIB stock a hold due to current uncertainties; will reconsider upon sustained revenue growth, regulatory approvals, or positive trial data. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
Biogen: Balancing Risks And Opportunities
Summary Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares is $149, close to the current price, leading to a "Hold" rating and a recommended purchase price of $115-120. Key growth drivers include potential success with Leqembi, Skyclarys, and optimization efforts, while risks involve slow sales of new products and competition. Despite a 35% stock price drop in 2024, Biogen's strategic steps and increased margins suggest shares are near fair value. Read the full article on Seeking AlphaSeeking Alpha • Feb 15
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Summary Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mirroring Aduhelm's failure, and Biogen's pipeline lacks promising products to drive future growth. The multiple sclerosis franchise is in decline, and new drug approvals like Qalsody and Skyclarys have shown minimal revenue impact. Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Read the full article on Seeking Alpha決済の安定と成長
配当データの取得
安定した配当: BIIBの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: BIIBの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Biogen 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (BIIB) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Biotechs) | 2.5% |
| アナリスト予想 (BIIB) (最長3年) | 0% |
注目すべき配当: BIIBは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: BIIBは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: BIIBの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: BIIBが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/07 14:17 |
| 終値 | 2026/05/07 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Biogen Inc. 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。58
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |